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INTRODUCTION
In spite of great incremental progress, the incidence and m ortality of breast cancer remain high. Molecular targeting is poised to enhance sensitivity and s pecificity of imaging and c an be simultaneously exploited for therapy. Tumor blood vessels are known to be different from vessels of normal tissues(1-3) and could offer unique molecular targets for developing molecular imaging or targeted therapeutics (4, 5) . The Objectives of this proposal are to develop targeted therapy tools directed against the breast cancer vasculature. The central hypothesis that we wish to test is that immune-gene therapy with T-bodies expressing CIR directed against tumor vascular targets and bi-or tripartite signaling modules circumvents many limitations in the field and represents a powerful approach to treat breast cancer. Our specific aims are: 1) Engineer T cells to express T-bodies that effectively target TEM1-positive vasculature using lentiviral transduction of chimeric immunoreceptors (CIR) comprising anti-TEM1 scFv, CD3ζ ,CD28 and/or 4-1BB; 2) Optimize T-bodies for safety by separating the anti-TEM1 CIR carrying CD3ζ (stimulatory) from a CIR recognizing prostate specific membrane antigen (PSMA), which will carry CD28 and/or 4-1BB (costimulatory). 3) Test T-bodies against breast cancer in vivo in orthotopic and metastatic breast cancer in mice. In the annual report submitted July 2011 we reported that five unique CIRs against hTEM1 were generated using scFv fragments isolated from a human derived yeast-display library. Among all the series of scFv tested, only scFv78 CIR bearing T cells were activated after co-culture with immobilized protein. However, such scFv78 CIR bearing T cells were not activated after co-culture with hTEM1 positive target cells. We tested hinges of different length; posited that the CD8α hinge did not sufficiently extend from the T cell surface, limiting the ability of scFv78 to interact with hTEM1 on the surface of the target cell lines. With a more flexible IgG4 hinge elongating the hinge region by 186 amino acids, such CIR bearing T cells incorporating this construct, unfortunately, also failed to activate in the presence of hTEM1 positive target cells.
BODY
In order to use anti-TEM1 PET to assist TEM1-specific adoptive therapy, we have engineered de novo TEM1-specific antibodies of scFv78 fused to human IgG1(Fc, CH2, CH3 and hinge). We have found that these multivalent constructs showed higher avidity, longer serum half-life in vitro, better blood pharmacokinetics and ability for direct 124-I labeling when compared to scFv78 we identified preciously(6) ( Figure 1 ). We are currently testing their applicability of immuno-PET. We also engineered a new yeastdisplay scFv library from patients with cancer instead of autoimmune condition (7), and a new recombinant TEM1 protein (rTEM1) expressed in mammalian cells instead of bacteria, to isolate a second generation of anti-TEM1 scFvs. These novel anti-TEM1 scFv were validated by ELISA assays for binding to recombinant proteins. However, despite satisfying binding to the recombinant protein rTEMs, we found that, as the first generation, the second generation anti-TEM1 scFv could not detect cell surface expressed TEM1. We changed model system and used different scFv isolated from the same library with the same method (8) to understand the limits of our system of selection. We found that while detection assays performed by flow cytometry analysis were not predictive of scFv function as CIRs, capture assays performed by ELISA assays were. We asked for a no-cost extension to retest the second generation of anti-TEM1 scFvs using BBIR transduced T cells (BBIR + T cells). BBIR + T cells recognize and bind exclusively to cancer cells pre-targeted with specific biotinylated molecules (9) . But again, we were unable to demonstrate specific killing targeted by anti-TEM1 scFv. We concluded that the current methods of scFv screening are not predictive of T cell targeting.
In parallel to hTEM1, we have identified several additional TVMs by quantitative real-time polymerase chain reaction (qRT-PCR) of tumor endothelial cells isolated by laser-capture microdissection (10) . These TVMs include tumor endothelial marker 5 (TEM5), tumor endothelial marker 7 (TEM7), CUB-domaincontaining protein 1 (CDCP1), endothelin receptor B (EDNRB), endocan (ESM-1), and Frizzled-10 (FZD10, or CD350). To generate antibodies against these TVMs, we first expressed the extracellular domain of each target antigens as soluble protein. We designed a panel of novel vectors utilizing various easy-to-express proteins (i.e. SUMO, Fc, the extracellular domain of mTEM7, etc.). Among all the vectors we constructed (Figure 2A) , TVMs fused to extracellular domain of mTEM7 yielded the highest expression ( Figure 2B ). Using these vectors, almost all of the antigens have been successfully produced, including the extracellular domains of hTEM5, mTEM5, hFAP, mCDCP1, hFZD10, mFZD10, hEDNRB, hSP17 and m SP17(Figure2). To isolate high affinity antibodies that target these novel tumor markers, we have constructed a novel yeast display library of human recombinant antibodies derived from B cells of ovarian cancer patients (7) . Using this library and our previous TTP patient derived scFv library, after several rounds of magnetic sorting, we have isolated antigen binding populations for hTEM1, hTEM5, hTEM7, hCDCP1, hFAP, hFZD10, hEDNRB, hESM-1 and hSPA17. We are currently characterizing the high affinity antibodies we isolated by flow cytometry based cell sorting and make CIRs constructs based on these scFvs to target above tumor vasculature markers.
Task 2. Optimize T-bodies for affinity and for safety a. Generate T-bodies transduced with hTEM1 CIR carrying signal 1 and PSMA/TEM7R CIR carrying signal 2 (and vice versa), using affinity-optimized scFv. b. Develop endothelial cells expressing hTEM1 only, PSMA only or both ligands for in vitro and vivo experiments. And c. prepare the lentivirus and test in vitro with T cells for targeting TEM1 endothelial cells in 2-D and 3-D culture by cytokine, proliferation, and cytotoxicity assays.
PSMA has been reported to express in breast carcimoma (11) . Immunohistochemistry was performed on a tissue microarray containing 13 primary ovarian cancer specimens. Over half of the samples expressed PSMA on the tumor vessels ( Figure 3) . Currently, the array is being analyzed to determine the percentage of positive vessels from each tumor core, and also the intensity of staining. Flow cytometry was also used to confirm the expression of PSMA on patient derived tumor endothelial cells. In previous annual report we constructed CIRs against PSMA using the PZ1 scFv. Among the series of lentiviral CIR vectors we constructed, which confer signaling through CD3ζ, CD28ζ, 4-1BBζ, or CD28BBζ. T cells bearing the PZ1 CIR with CD28ζ signaling produce the most robust polyfunctional repertoire of pro-inflammatory cytokines. PSMA isoform 1 is the most abundant PSMA isoform detected in prostate cancer, whereas PSMA isoform 2 has greater prevalence in benign tissue. For this reason, we hypothesize that PSMA isoform 1 may be physiologically relevant in the tumor neovasculature as well. We have characterized the ability of the Pz1 chimeric antigen receptor to specifically recognize PSMA the membrane bound and the cytosolic isoform. Immortalized human microvascular endothelial cells, HMEC-1, were transduced to express either isoform 1 or 2. Pz1 CAR bearing T cells were co-cultured with HMEC-1, HMEC-1PSMA1, or HMEC-1PSMA2, and revealed exclusive specificity for the HMEC-1 cells that expressed PSMA isoform 1. This restriction in specificity allows CIR bearing T cells to distinguish between the two prevalent membrane isoforms of PSMA, and highlights a potential safety feature of the Pz1 scFv should the isoform distribution be unique between the normal and tumor blood vessels.
Task 3. Test T-bodies against breast cancer in vivo.
a. Establish human endothelium xenografts in the NSG(NOD/SCID/γc-/-) mouse model by injection breast cancer cell mixed with immortalized endothelial cells stably expressing TEM1 subcutaneously into the mammary pads (orthotopic) and the flank or the liver (metastatic). Observe in vivo by PET and bioluminescence. b. Determine whether xenografts harbor functional vasculature from the xenograft by histochemical and immunohistochemical assays. c. Determine if the function of T-cells tranduced with CIR against TEM1 with Winn assay and after injection intratumorally, intravenously, by tumor volume, bioluminescence, PET and MRI.
A significant hurdle in testing anti-vascular agents is the availability of animal models expressing human vascular targets. In previous annual report. we have developed the first mouse model of tumor endothelium expressing human TEM1 in immunodeficient mice in vivo. In parallel to the development of this xenograft mouse model, we also engineered MS1 cells to express human PSMA and both hTEM1 and PSMA. These models will be used to test the ability of first generation (single CIR) and second generation (split-signal1 and signal 2 CIR) T cells transferred intravenously to reject TEM1+ PSMA+ tumors in vivo.
Using above model, we also established TEM1-specific molecular PET imaging of hTEM1-expressing tumor vasculature with [124I]-MORAb-004. PET images of [124I]-MORAb-004 distribution 18 h following intravenous administration (5 μg/mouse) revealed excellent uptake in mice with tumors harboring hTEM1-positive vasculature, with negligible uptake in tumors whose vasculature did not express hTEM1 or in the blood pool, and abdomen.
A major concern of adoptive T cells therapy is safety. To provide a s econd layer of safety, we hypothesize that a s uicide gene can be used to transduce CIR-bearing T cells. The herpes simplex virus-1 thymidine kinase (HSV1-tk) gene is a good candidate since it also enables tracing the T-cells with FIAU/FHBG PET.
We have constructed a panel of lentiviral vectors with different promoters driving HSV-TK and h ave tested for the level of expression (Figure 4) . These experiments will help us make decisions regarding optimization of TK expression. Human primary CD4 T cells were infected with lentivirus coding HSV-TK under different promoters (CMV, EF1a MSCV, and Ubi). Cells were treated with 0.5ug/mL puromycin for 3 days, then analyzed for vitality (7-AAD negative) and expression of GFP-puro. We have found that MSCV promoter is the best candidate as CMV quickly loses its promoter activity. Currently, we are testing the RNA and protein level of HSV-tk in these T-cells and optimizing our protocol for expansion of the puromycine-selected T cells. We plan to evaluate the function of the promoter-optimized HSV-tk T-cells in in vitro and vivo killing-assays using ganciclovir as suicide treatment. We have set up P ET with 18 F-FHBG and 124 I-FIAU, so that we are able to evaluate tracking the location of adoptive T cells in vivo to estimate their quantity in the tumor and follow their fate in time.
KEY RESEARCH ACCOMPLISHMENTS:
-We developed first generation CIR lentiviral vector constructs targeting hTEM1 with a panel of scFvs of different affinity (2nM to 4uM). These constructs containing CD3 AND costimulatory molecules (CD28 and 4-1BB). However, no activation was observed when co-culture was performed with target cells expressing hTEM1 on the surface. -We engineered a new library of human recombinant antibodies from ovarian cancer patients that was used to screen for additional anti-TEM1 scFv. -In parallel to hTEM1, we have developed de novo mammalian expression vectors for expressing additional TVMs. These TVMs are purified and used to pan our scFv library. -We have generated CIRs against PSMA using scFv (PZ1). PZ1 CIR bearing T cells recognize only PSMA isoform 1 but not isoform 2. 
